Yantai Zhenghai Bio-Tech Co Ltd

Zhenghai Bio released its 2026 interim report, with net profit attributable to the parent company at 33.31 million yuan, down 27.85% from the same period last year. Total operating revenue was 160 million yuan, down 14.94% year-on-year. Net cash flow from operating activities was 28.29 million yuan, down 40.65% year-on-year. The company's latest asset-liability ratio was 9.97%, gross margin was 82.37%, return on equity was 3.81%, and diluted earnings per share was 0.19 yuan.

Zhenghai Bio-Tech released its 2026 interim report. First-half net profit attributable to the parent was 33.31 million yuan, down 27.85% year on year. Operating revenue was 160 million yuan, down 14.94% year on year. Net profit attributable to the parent after deducting non-recurring items was 27.16 million yuan, down 31.74% year on year. Net operating cash flow was 28.29 million yuan, down 40.65% year on year. Second-quarter net profit attributable to the parent was 18.56 million yuan, down 6.6% year on year. The company said its main business has not undergone major changes and remains focused on regenerative medicine, mainly providing Class III medical device products.